SCHEMBL4284884

SCHEMBL4284884

CN(C)CC(=O)Nc1n[nH]c2ccc(-c3cnn(Cc4ccccc4)c3)cc12

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDC7 O00311 18/20 0.75
DAPK3 O43293 12/20 0.75
CLK2 P49760 12/20 0.75
CDK5 Q00535 12/20 0.75
DYRK1A Q13627 12/20 0.75
HIPK2 Q9H2X6 12/20 0.75
MAP4K5 Q9Y4K4 11/20 0.75
CDK2 P24941 11/20 0.75
PRKACA P17612 9/20 0.75
ROCK2 O75116 8/20 0.75
AURKB Q96GD4 7/20 0.75
GSK3B P49841 7/20 0.75
PRKD3 O94806 7/20 0.75
MAPK13 O15264 6/20 0.75
CDK1 P06493 6/20 0.75
MAPK1 P28482 6/20 0.75
MAPK9 P45984 6/20 0.75
MAPK12 P53778 6/20 0.75
CSNK2A1 P68400 6/20 0.75
CSNK1G2 P78368 6/20 0.75

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4289209 0.85 CDC7 (1.00) CDC7DAPK3CLK2CDK5DYRK1A
SCHEMBL3665794 0.84 GSK3B (0.58) CDC7DAPK3CLK2CDK5DYRK1A
SCHEMBL3668979 0.81 DYRK1A (0.54) CDC7DAPK3CLK2CDK5DYRK1A
SCHEMBL3670129 0.78 GSK3B (0.56) CDC7DAPK3CLK2CDK5DYRK1A
SCHEMBL4295540 0.77 CDC7 (0.84) CDC7DAPK3CLK2CDK5DYRK1A
SCHEMBL3675188 0.77 GSK3B (0.58) CDC7DAPK3CLK2CDK5DYRK1A
SCHEMBL4289104 0.77 CDC7 (0.84) CDC7DAPK3CLK2CDK5DYRK1A
SCHEMBL3804773 0.76 GSK3B (0.55) CDC7DAPK3CLK2CDK5DYRK1A
SCHEMBL4286164 0.76 CDC7 (0.82) CDC7DAPK3CLK2CDK5DYRK1A
SCHEMBL4289897 0.76 CDC7 (0.70) CDC7DAPK3CLK2CDK5DYRK1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090203690-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS ABBOTT LABORATORIES (US) 2009-08-13 US claimed
US-9163007-B2 5-substituted indazoles as kinase inhibitors ABBVIE INC. (US) 2015-10-20 US disclosed
US-20140343066-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS AbbVie Deutschland GmbH & Co. KG (DE) 2014-11-20 US disclosed
US-8648069-B2 5-substituted indazoles as kinase inhibitors ABBVIE INC. (US) 2014-02-11 US disclosed
US-20090203690-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS ABBOTT LABORATORIES (US) 2009-08-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140343066-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS GSK3B, GSK3A, PIM3 CDC7 8/4885DAPK3 226/4885CLK2 115/4885
US-20090203690-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS GSK3B, GSK3A, PIM3 CDC7 8/4885DAPK3 226/4885CLK2 115/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.